

1  
2  
**UNITED STATES DISTRICT COURT**  
**FOR THE DISTRICT OF NEVADA**

3 FERRING B.V.

4 Plaintiff,

5 v.

6 APOTEX INC. and APOTEX CORP.,

7 Defendants.

Case Nos.:

3:11-cv-00481-RCJ-VPC (Lead Case)  
3:11-cv-00485-RCJ-VPC  
3:11-cv-00854-RCJ-VPC  
2:12-cv-01941-RCJ-VPC

(Consolidated)

8  
9 **JUDGMENT**

10 This action for patent infringement having been brought by Plaintiff Ferring B.V.  
11 (“Plaintiff” or “Ferring”) against Defendants Apotex Inc. and Apotex Corp. (“collectively,  
12 “Defendants” or “Apotex”) for infringement of United States Patent Nos. 7,947,739 (‘the ’739  
13 patent’). 8,022,106 (“the ’106 patent’); and 8,273,795 (“the ’795 patent’) (collectively, “patents-  
14 in-suit’”):

15 The Court having found that Apotex’s approved ANDA No. 202286 infringed Plaintiff’s  
16 above-referenced patents;

17 Apotex having Stipulated to amend its ANDA No. 202286 request with the FDA; and


18 The Court having acknowledged that Apotex’s action moots Plaintiff’s Complaint with  
19 regard to Apotex’s proposed ANDA amendment.

20 **IT IS THEREFORE ORDERED AND ADJUDGED** that:

21 1. This action is dismissed pursuant to the stipulation of Apotex made on the record  
22 and incorporated by reference and filed under seal.

23 2. Each party is to bear its own costs and attorneys’ fees.

24 **So Ordered, Adjudged and Signed this** 24th day of March, 2014.

25  
26  
27  
28   
\_\_\_\_\_  
UNITED STATES DISTRICT JUDGE